Crossmark

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report

Crossref DOI link: https://doi.org/10.1186/s12881-018-0703-9

Published Online: 2018-10-17

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ma, Yi

He, Lijie https://orcid.org/0000-0002-0586-5877
Huang, Qianwen

Zheng, Shuang

Zhang, Zhiqiang

Li, Hongshi

Liu, Shuang
License Information

Text and Data Mining valid from 2018-10-17
More Information

Article History

Received: 12 April 2018

Accepted: 2 October 2018

First Online: 17 October 2018

Ethics approval and consent to participate

: The publication of this manuscript has been reviewed and approved by the People’s Hospital of Liaoning Province institutional review board.

: The patient and his family have consent to publish the manuscript.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.